2023
HIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease
Little A, Chen P, Vesely M, Khan R, Fiedler J, Garritano J, Islam F, McNiff J, Craft J. HIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease. JCI Insight 2023, 8: e166076. PMID: 37526979, PMCID: PMC10543720, DOI: 10.1172/jci.insight.166076.Peer-Reviewed Original ResearchConceptsCutaneous lupus erythematosusLupus skin diseaseT cellsSkin diseasesCytotoxic signatureInflammatory infiltrateHIF-1Tissue damageKidney-infiltrating T cellsSkin-infiltrating T cellsAutoimmune skin diseaseHIF-1 inhibitionSkin tissue damageLupus erythematosusSystemic diseaseTissue inflammationGranzyme BMouse modelInflammatory gene programDiseaseProtein levelsInfiltratesSkin environmentGene programPresent study
2013
CD301b+ Dermal Dendritic Cells Drive T Helper 2 Cell-Mediated Immunity
Kumamoto Y, Linehan M, Weinstein JS, Laidlaw BJ, Craft JE, Iwasaki A. CD301b+ Dermal Dendritic Cells Drive T Helper 2 Cell-Mediated Immunity. Immunity 2013, 39: 733-743. PMID: 24076051, PMCID: PMC3819035, DOI: 10.1016/j.immuni.2013.08.029.Peer-Reviewed Original ResearchConceptsDermal dendritic cellsDendritic cellsDermal DCsTh2 cellsT cellsT helper 2 cellsT helper responsesInterleukin-4 productionExpression of CD69Th2 cell developmentDC depletionLymph nodesTh2 immunityHelper responsesSubcutaneous immunizationNippostrongylus brasiliensisKey mediatorTransient depletionCell developmentImmunityOvalbuminDepletion approachCellsParticular subsetCD301b
2012
IL-21 Receptor Is Required for the Systemic Accumulation of Activated B and T Lymphocytes in MRL/MpJ-Faslpr/lpr/J Mice
Rankin AL, Guay H, Herber D, Bertino SA, Duzanski TA, Carrier Y, Keegan S, Senices M, Stedman N, Ryan M, Bloom L, Medley Q, Collins M, Nickerson-Nutter C, Craft J, Young D, Dunussi-Joannopoulos K. IL-21 Receptor Is Required for the Systemic Accumulation of Activated B and T Lymphocytes in MRL/MpJ-Faslpr/lpr/J Mice. The Journal Of Immunology 2012, 188: 1656-1667. PMID: 22231702, PMCID: PMC3618484, DOI: 10.4049/jimmunol.1003871.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoantibodiesAutoimmunityB-LymphocytesCD4-Positive T-LymphocytesCell DifferentiationInterferon-gammaInterleukinsLupus Erythematosus, SystemicLymphatic DiseasesLymphocyte ActivationMiceMice, Inbred MRL lprMice, KnockoutReceptors, Interleukin-21SkinSplenomegalyT-Lymphocyte SubsetsT-Lymphocytes, Helper-InducerConceptsT cell effector subsetsIL-21Effector subsetsIL-21RT cellsHelper cellsSpontaneous germinal center formationIL-21-dependent mannerIL-21 receptorMRL/MpJPlasma cell accumulationGerminal center formationTh cell differentiationSignificant reductionAutoantibody titersAutoantibody productionCytokines IFNImmune activationSystemic autoimmunityJ miceDisease manifestationsT lymphocytesPleiotropic cytokineB cellsDisease pathogenesis
2009
Barrier immunity and IL-17
Marks BR, Craft J. Barrier immunity and IL-17. Seminars In Immunology 2009, 21: 164-171. PMID: 19386512, PMCID: PMC2692766, DOI: 10.1016/j.smim.2009.03.001.Peer-Reviewed Original Research
1983
The Spirochetal Etiology of Lyme Disease
Steere A, Grodzicki R, Kornblatt A, Craft J, Barbour A, Burgdorfer W, Schmid G, Johnson E, Malawista S. The Spirochetal Etiology of Lyme Disease. New England Journal Of Medicine 1983, 308: 733-740. PMID: 6828118, DOI: 10.1056/nejm198303313081301.Peer-Reviewed Original ResearchConceptsLyme diseaseAntibody titersIgM titersSpecific IgM antibody titersSpecific IgG antibody titersElevated IgM titersI. dammini spirocheteIgG antibody titersIgM antibody titersTiters of IgGOnset of diseaseInfectious mononucleosisControl patientsImmunologic featuresIgG titersEarly diseaseControl subjectsSpirochetal etiologySkin lesionsCerebrospinal fluidPatientsLate manifestationSixth weekDiseaseTiters